Retrospective Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Dec 24, 2016; 6(4): 697-702
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.697
Tacrolimus confers lower acute rejection rates and better renal allograft survival compared to cyclosporine
Mahmoud Kamel, Manish Kadian, Titte Srinivas, David Taber, Maria Aurora Posadas Salas
Mahmoud Kamel, Manish Kadian, Titte Srinivas, Maria Aurora Posadas Salas, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, United States
David Taber, Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, United States
Author contributions: Kamel M contributed to data collection, manuscript writing, and manuscript revision; Kadian M contributed to data collection and manuscript writing; Srinivas T contributed to study design and manuscript revision; Taber D contributed to study design, data analysis, and manuscript revision; Posadas Salas MA contributed to study design, data collection, manuscript writing, and manuscript revision.
Institutional review board statement: This study was reviewed and approved by the Medical University of South Carolina Institutional Review Board (IRB).
Informed consent statement: Retrospective analysis was performed on deidentified clinical data. After review, the IRB waived the requirements for individual informed consent because the study was considered minimal risk and strict safeguards are in place to ensure confidentiality of those included in the analysis.
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maria Aurora Posadas Salas, MD, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC 29425, United States. posadas@musc.edu
Telephone: +1-843-7922123 Fax: +1-843-7928399
Received: April 28, 2016
Peer-review started: April 28, 2016
First decision: July 5, 2016
Revised: September 1, 2016
Accepted: September 21, 2016
Article in press: September 23, 2016
Published online: December 24, 2016
Processing time: 229 Days and 22.8 Hours
Core Tip

Core tip: Tacrolimus (FK) has surpassed cyclosporine (CYA) as the calcineurin inhibitor (CNI) of choice for the vast majority of kidney transplant (KTX) programs. Yet, CYA continues to be an important alternative for patients intolerant to FK. FK is associated with significantly lower rate of acute rejection and better graft survival compared to CYA. Individualizing immunosuppression through risk-stratified CNI choice may lead to improved outcomes across all spectra of KTX patients.